Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00486759




Registration number
NCT00486759
Ethics application status
Date submitted
14/06/2007
Date registered
15/06/2007
Date last updated
25/07/2017

Titles & IDs
Public title
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
Scientific title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial Comparing the Efficacy of Bevacizumab in Combination With Rituximab and CHOP (R-CHOP + Bevacizumab) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)
Secondary ID [1] 0 0
BO20603
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
B-cell Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Bevacizumab
Treatment: Drugs - Rituximab
Treatment: Drugs - CHOP
Treatment: Drugs - Placebo

Experimental: Bevacizumab + rituximab + CHOP - Patients received bevacizumab 5 mg/kg/week on Day 1 of each cycle + rituximab 375 mg/m\^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone).

Active comparator: Placebo + rituximab + CHOP - Patients received placebo to bevacizumab on Day 1 of each cycle + rituximab 375 mg/m\^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone).


Treatment: Drugs: Bevacizumab
Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

Treatment: Drugs: Rituximab
Rituximab was administered at a dose of 375 mg/m\^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

Treatment: Drugs: CHOP
Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m\^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m\^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

Treatment: Drugs: Placebo
Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS)
Timepoint [1] 0 0
Baseline to end of the study (up to 4 years, 4 months)
Secondary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
Baseline to end of the study (up to 4 years, 4 months)
Secondary outcome [2] 0 0
Overall Response (OR) Assessed According to the Revised Response Criteria for Malignant Lymphoma
Timepoint [2] 0 0
At the end of treatment (Cycle 8, up to 12 months)

Eligibility
Key inclusion criteria
* Adult patients, = 18 and < 80 years of age.
* CD20-positive diffuse large B-cell lymphoma.
* Low-intermediate, high-intermediate, or high risk disease and/or bulky tumor (largest diameter = 7.5 cm).
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Minimum age
18 Years
Maximum age
79 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior treatment for diffuse large B-cell lymphoma.
* Types of non-Hodgkin's lymphoma other than diffuse large B-cell lymphoma (DLBCL).
* Central nervous system (CNS) involvement of lymphoma.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/07/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/11/2011
Sample size
Target
Accrual to date
Final
787
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Greenslopes Private Hospital; Gallipoli Research Centre - Greenslopes
Recruitment hospital [2] 0 0
Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology - Woolloongabba
Recruitment hospital [3] 0 0
Royal Adelaide Hospital; Haematology, Institute of Medical Veterinary Science - Adelaide
Recruitment hospital [4] 0 0
Ashford Cancer Center Research - Kurralta Park
Recruitment hospital [5] 0 0
Frankston Hospital; Oncology/Haematology - Frankston
Recruitment hospital [6] 0 0
Peter Maccallum Cancer Institute; Medical Oncology - Melbourne
Recruitment hospital [7] 0 0
Alfred Hospital; Bone Marrow Transplant Unit - Melbourne
Recruitment hospital [8] 0 0
Border Medical Oncology; Murray Valley Private Hospital - Wodonga
Recruitment hospital [9] 0 0
Fremantle Hospital; Haematology - Fremantle
Recruitment postcode(s) [1] 0 0
4120 - Greenslopes
Recruitment postcode(s) [2] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [5] 0 0
3199 - Frankston
Recruitment postcode(s) [6] 0 0
3000 - Melbourne
Recruitment postcode(s) [7] 0 0
3181 - Melbourne
Recruitment postcode(s) [8] 0 0
3690 - Wodonga
Recruitment postcode(s) [9] 0 0
6160 - Fremantle
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
North Carolina
Country [8] 0 0
United States of America
State/province [8] 0 0
Oregon
Country [9] 0 0
United States of America
State/province [9] 0 0
South Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
United States of America
State/province [11] 0 0
Washington
Country [12] 0 0
Argentina
State/province [12] 0 0
Buenos Aires
Country [13] 0 0
Argentina
State/province [13] 0 0
Córdoba
Country [14] 0 0
Austria
State/province [14] 0 0
Graz
Country [15] 0 0
Austria
State/province [15] 0 0
Salzburg
Country [16] 0 0
Austria
State/province [16] 0 0
Wien
Country [17] 0 0
Brazil
State/province [17] 0 0
GO
Country [18] 0 0
Brazil
State/province [18] 0 0
RS
Country [19] 0 0
Brazil
State/province [19] 0 0
SP
Country [20] 0 0
Canada
State/province [20] 0 0
Alberta
Country [21] 0 0
Canada
State/province [21] 0 0
Manitoba
Country [22] 0 0
Canada
State/province [22] 0 0
New Brunswick
Country [23] 0 0
Canada
State/province [23] 0 0
Newfoundland and Labrador
Country [24] 0 0
Canada
State/province [24] 0 0
Nova Scotia
Country [25] 0 0
Canada
State/province [25] 0 0
Ontario
Country [26] 0 0
Canada
State/province [26] 0 0
Quebec
Country [27] 0 0
Canada
State/province [27] 0 0
Saskatchewan
Country [28] 0 0
China
State/province [28] 0 0
Beijing
Country [29] 0 0
China
State/province [29] 0 0
Fuzhou
Country [30] 0 0
China
State/province [30] 0 0
Shanghai
Country [31] 0 0
China
State/province [31] 0 0
Suzhou
Country [32] 0 0
China
State/province [32] 0 0
Tianjin
Country [33] 0 0
China
State/province [33] 0 0
Xi'an
Country [34] 0 0
Colombia
State/province [34] 0 0
Bogota
Country [35] 0 0
Colombia
State/province [35] 0 0
Medellin-Antioquia
Country [36] 0 0
Colombia
State/province [36] 0 0
Medellin
Country [37] 0 0
Colombia
State/province [37] 0 0
Pereira
Country [38] 0 0
Czechia
State/province [38] 0 0
Brno
Country [39] 0 0
Czechia
State/province [39] 0 0
Hradec Kralove
Country [40] 0 0
Czechia
State/province [40] 0 0
Olomouc
Country [41] 0 0
Czechia
State/province [41] 0 0
Plzen - Lochotin
Country [42] 0 0
Czechia
State/province [42] 0 0
Praha 2
Country [43] 0 0
Czechia
State/province [43] 0 0
Praha
Country [44] 0 0
Ecuador
State/province [44] 0 0
Guayaquil
Country [45] 0 0
Ecuador
State/province [45] 0 0
Quito
Country [46] 0 0
France
State/province [46] 0 0
Albi
Country [47] 0 0
France
State/province [47] 0 0
Angers
Country [48] 0 0
France
State/province [48] 0 0
Bordeaux
Country [49] 0 0
France
State/province [49] 0 0
Caen
Country [50] 0 0
France
State/province [50] 0 0
Clermont Ferrand
Country [51] 0 0
France
State/province [51] 0 0
Dijon
Country [52] 0 0
France
State/province [52] 0 0
La Roche Sur Yon
Country [53] 0 0
France
State/province [53] 0 0
La Tronche
Country [54] 0 0
France
State/province [54] 0 0
Le Mans
Country [55] 0 0
France
State/province [55] 0 0
Lille
Country [56] 0 0
France
State/province [56] 0 0
Limoges
Country [57] 0 0
France
State/province [57] 0 0
Lyon
Country [58] 0 0
France
State/province [58] 0 0
Marseille
Country [59] 0 0
France
State/province [59] 0 0
Montauban
Country [60] 0 0
France
State/province [60] 0 0
Montpellier
Country [61] 0 0
France
State/province [61] 0 0
Nice
Country [62] 0 0
France
State/province [62] 0 0
Nimes
Country [63] 0 0
France
State/province [63] 0 0
Paris
Country [64] 0 0
France
State/province [64] 0 0
Perpignan
Country [65] 0 0
France
State/province [65] 0 0
Pessac
Country [66] 0 0
France
State/province [66] 0 0
Pierre Benite
Country [67] 0 0
France
State/province [67] 0 0
Poitiers
Country [68] 0 0
France
State/province [68] 0 0
Rodez
Country [69] 0 0
France
State/province [69] 0 0
Saint-Priest en Jarez
Country [70] 0 0
France
State/province [70] 0 0
Salouel
Country [71] 0 0
France
State/province [71] 0 0
Toulouse
Country [72] 0 0
France
State/province [72] 0 0
Tours
Country [73] 0 0
France
State/province [73] 0 0
Vandoeuvre Les Nancy
Country [74] 0 0
France
State/province [74] 0 0
Villejuif
Country [75] 0 0
Germany
State/province [75] 0 0
Amberg
Country [76] 0 0
Germany
State/province [76] 0 0
Berlin
Country [77] 0 0
Germany
State/province [77] 0 0
Bremen
Country [78] 0 0
Germany
State/province [78] 0 0
Cottbus
Country [79] 0 0
Germany
State/province [79] 0 0
Dortmund
Country [80] 0 0
Germany
State/province [80] 0 0
Eschweiler
Country [81] 0 0
Germany
State/province [81] 0 0
Frankfurt
Country [82] 0 0
Germany
State/province [82] 0 0
Fulda
Country [83] 0 0
Germany
State/province [83] 0 0
Greifswald
Country [84] 0 0
Germany
State/province [84] 0 0
Göttingen
Country [85] 0 0
Germany
State/province [85] 0 0
Hagen
Country [86] 0 0
Germany
State/province [86] 0 0
Hamburg
Country [87] 0 0
Germany
State/province [87] 0 0
Hamm
Country [88] 0 0
Germany
State/province [88] 0 0
Hannover
Country [89] 0 0
Germany
State/province [89] 0 0
Hildesheim
Country [90] 0 0
Germany
State/province [90] 0 0
Homburg/Saar
Country [91] 0 0
Germany
State/province [91] 0 0
Karlsruhe
Country [92] 0 0
Germany
State/province [92] 0 0
Landshut
Country [93] 0 0
Germany
State/province [93] 0 0
Leipzig
Country [94] 0 0
Germany
State/province [94] 0 0
Ludwigshafen
Country [95] 0 0
Germany
State/province [95] 0 0
Lübeck
Country [96] 0 0
Germany
State/province [96] 0 0
Lüdenscheid
Country [97] 0 0
Germany
State/province [97] 0 0
Magdeburg
Country [98] 0 0
Germany
State/province [98] 0 0
Mannheim
Country [99] 0 0
Germany
State/province [99] 0 0
Muenchen
Country [100] 0 0
Germany
State/province [100] 0 0
Münster
Country [101] 0 0
Germany
State/province [101] 0 0
Oldenburg
Country [102] 0 0
Germany
State/province [102] 0 0
Recklinghausen
Country [103] 0 0
Germany
State/province [103] 0 0
Siegen
Country [104] 0 0
Germany
State/province [104] 0 0
Trier
Country [105] 0 0
Germany
State/province [105] 0 0
Tübingen
Country [106] 0 0
Germany
State/province [106] 0 0
Ulm
Country [107] 0 0
Germany
State/province [107] 0 0
Wiesbaden
Country [108] 0 0
Germany
State/province [108] 0 0
Wuppertal
Country [109] 0 0
Greece
State/province [109] 0 0
Thessaloniki
Country [110] 0 0
Hong Kong
State/province [110] 0 0
Hong Kong
Country [111] 0 0
Hungary
State/province [111] 0 0
Budapest
Country [112] 0 0
Hungary
State/province [112] 0 0
Debrecen
Country [113] 0 0
Italy
State/province [113] 0 0
Emilia-Romagna
Country [114] 0 0
Italy
State/province [114] 0 0
Friuli-Venezia Giulia
Country [115] 0 0
Italy
State/province [115] 0 0
Lazio
Country [116] 0 0
Italy
State/province [116] 0 0
Lombardia
Country [117] 0 0
Italy
State/province [117] 0 0
Marche
Country [118] 0 0
Italy
State/province [118] 0 0
Molise
Country [119] 0 0
Italy
State/province [119] 0 0
Piemonte
Country [120] 0 0
Italy
State/province [120] 0 0
Puglia
Country [121] 0 0
Italy
State/province [121] 0 0
Sicilia
Country [122] 0 0
Italy
State/province [122] 0 0
Toscana
Country [123] 0 0
Korea, Republic of
State/province [123] 0 0
Seoul
Country [124] 0 0
Lithuania
State/province [124] 0 0
Klaipeda
Country [125] 0 0
Lithuania
State/province [125] 0 0
Vilnius
Country [126] 0 0
Malaysia
State/province [126] 0 0
Penang
Country [127] 0 0
Mexico
State/province [127] 0 0
Aguascalientes
Country [128] 0 0
Mexico
State/province [128] 0 0
Mexico City
Country [129] 0 0
Mexico
State/province [129] 0 0
Monterrey
Country [130] 0 0
New Zealand
State/province [130] 0 0
Auckland
Country [131] 0 0
New Zealand
State/province [131] 0 0
Christchurch
Country [132] 0 0
Panama
State/province [132] 0 0
Panama City
Country [133] 0 0
Peru
State/province [133] 0 0
Chiclayo
Country [134] 0 0
Peru
State/province [134] 0 0
Lima
Country [135] 0 0
Philippines
State/province [135] 0 0
Cebu
Country [136] 0 0
Philippines
State/province [136] 0 0
Diliman, Quezon City
Country [137] 0 0
Philippines
State/province [137] 0 0
Quezon City
Country [138] 0 0
Poland
State/province [138] 0 0
Brzozów
Country [139] 0 0
Poland
State/province [139] 0 0
Krakow
Country [140] 0 0
Poland
State/province [140] 0 0
Lodz
Country [141] 0 0
Poland
State/province [141] 0 0
Lublin
Country [142] 0 0
Poland
State/province [142] 0 0
Olsztyn
Country [143] 0 0
Poland
State/province [143] 0 0
Warszawa
Country [144] 0 0
Portugal
State/province [144] 0 0
Coimbra
Country [145] 0 0
Portugal
State/province [145] 0 0
Lisboa
Country [146] 0 0
Portugal
State/province [146] 0 0
Porto
Country [147] 0 0
Russian Federation
State/province [147] 0 0
Kazan
Country [148] 0 0
Russian Federation
State/province [148] 0 0
Moscow
Country [149] 0 0
Russian Federation
State/province [149] 0 0
St Petersburg
Country [150] 0 0
Slovakia
State/province [150] 0 0
Bratislava
Country [151] 0 0
Spain
State/province [151] 0 0
Barcelona
Country [152] 0 0
Spain
State/province [152] 0 0
Cantabria
Country [153] 0 0
Spain
State/province [153] 0 0
La Coruña
Country [154] 0 0
Spain
State/province [154] 0 0
Tenerife
Country [155] 0 0
Spain
State/province [155] 0 0
Vizcaya
Country [156] 0 0
Spain
State/province [156] 0 0
Jaen
Country [157] 0 0
Spain
State/province [157] 0 0
Madrid
Country [158] 0 0
Spain
State/province [158] 0 0
Malaga
Country [159] 0 0
Spain
State/province [159] 0 0
Salamanca
Country [160] 0 0
Spain
State/province [160] 0 0
Sevilla
Country [161] 0 0
Spain
State/province [161] 0 0
Valencia
Country [162] 0 0
Spain
State/province [162] 0 0
Zaragoza
Country [163] 0 0
Sweden
State/province [163] 0 0
Lund
Country [164] 0 0
Sweden
State/province [164] 0 0
Malmö
Country [165] 0 0
Sweden
State/province [165] 0 0
Sundsvall
Country [166] 0 0
Sweden
State/province [166] 0 0
Uppsala
Country [167] 0 0
Switzerland
State/province [167] 0 0
Zürich
Country [168] 0 0
Taiwan
State/province [168] 0 0
Taipei
Country [169] 0 0
Taiwan
State/province [169] 0 0
Taoyuan
Country [170] 0 0
Thailand
State/province [170] 0 0
Bangkok
Country [171] 0 0
Thailand
State/province [171] 0 0
Chiang Mai
Country [172] 0 0
Thailand
State/province [172] 0 0
Khon Kaen
Country [173] 0 0
United Kingdom
State/province [173] 0 0
Birmingham
Country [174] 0 0
United Kingdom
State/province [174] 0 0
Bradford
Country [175] 0 0
United Kingdom
State/province [175] 0 0
Hampshire
Country [176] 0 0
United Kingdom
State/province [176] 0 0
Harlow
Country [177] 0 0
United Kingdom
State/province [177] 0 0
Leicester
Country [178] 0 0
United Kingdom
State/province [178] 0 0
Liverpool
Country [179] 0 0
United Kingdom
State/province [179] 0 0
London
Country [180] 0 0
United Kingdom
State/province [180] 0 0
Middx
Country [181] 0 0
United Kingdom
State/province [181] 0 0
Oxford
Country [182] 0 0
United Kingdom
State/province [182] 0 0
Sheffield
Country [183] 0 0
United Kingdom
State/province [183] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Genentech, Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This 2-arm study was designed to compare the efficacy and safety of bevacizumab (Avastin) in combination with rituximab (MabThera) and CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone) chemotherapy (R-CHOP) versus rituximab plus CHOP chemotherapy (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL). Patients were randomized to receive 8 cycles of treatment with R-CHOP plus bevacizumab or R-CHOP plus placebo. Treatment with bevacizumab/placebo and R-CHOP was given either on a 2-week or 3-week schedule and bevacizumab was given at a weekly average dose of 5 mg/kg (10 mg/kg for 2-week cycles and 15 mg/kg for 3-week cycles).
Trial website
https://clinicaltrials.gov/study/NCT00486759
Trial related presentations / publications
McCord R, Bolen CR, Koeppen H, Kadel EE 3rd, Oestergaard MZ, Nielsen T, Sehn LH, Venstrom JM. PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv. 2019 Feb 26;3(4):531-540. doi: 10.1182/bloodadvances.2018020602.
Seymour JF, Pfreundschuh M, Trneny M, Sehn LH, Catalano J, Csinady E, Moore N, Coiffier B; MAIN Study Investigators. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica. 2014 Aug;99(8):1343-9. doi: 10.3324/haematol.2013.100818. Epub 2014 Jun 3.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00486759